• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Latest News

Melissa Krebs Shares GelSana’s Vision for Innovative Wound Care Solutions
Melissa Krebs Shares GelSana’s Vision for Innovative Wound Care Solutions

September 10th 2024

In this interview, Melissa Krebs, CEO and founder of GelSana, shares her journey in developing cutting-edge biomaterials that could transform the $78 billion wound care market.

Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer
Zongertinib Demonstrates High Objective Response Rate in Previously Treated Advanced Non-Small Cell Lung Cancer

September 10th 2024

stock.adobe.com
TC BioPharm Announces Plans for Mpox Treatment Studies

September 10th 2024

The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of Medicine
The AI Paradigm Shift: How Cutting-Edge Tech is Fast-Tracking the Future of Medicine

September 10th 2024

Big Bets, Bold Steps

Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology.

 Ken Keller, CEO of Daiichi Sankyo’s US business, reflects on the trials, triumphs, and lessons learned in steering the transformation of a legacy cardiovascular company into a global leader in oncology.

Conference Coverage

View All
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma

June 4th 2024

Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection
Moderna, Merck Present Promising Trial Data for a Combination of V940 with Keytruda for the Treatment of High-Risk Melanoma Following Complete Resection

June 4th 2024

Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer
Phase III Trial Data Presented at ASCO Show Imfinzi Improves Survival in Limited-Stage Small Cell Lung Cancer

June 3rd 2024

Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status
Data Presented at ASCO Show Improved Complete Response with Jemperli as a First-Line Treatment for Locally Advanced Rectal Cancer in Patients with Mismatch Repair Deficient Status

June 3rd 2024

Latest Videos
Podcasts

All News